Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens

• Main Authors: Elizabeth Marrett (Author), Winghan Jacqueline Kwong (Author), Jipan Xie (Author), Ameur M. Manceur (Author), Selvam R. Sendhil (Author), Eric Wu (Author), Raluca Ionescu-Ittu (Author), Janakiraman Subramanian (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR TKIs) are established first-line treatments among patients with metastatic non-small cell lung cancer harboring EGFR-sensitizing mutations. Upon EGFR TKI resistance, there are scant data supporting a standard of ca...